胡文輝(廣州醫科大學藥學院特聘教授)

胡文輝博士，現任廣州醫科大學藥學院特聘教授，藥物化學專業博士生導師，兼學術委員會主任，廣東省分子靶標與臨床藥理重點實驗室副主任,呼吸病國家重點實驗室研究員。

胡博士於2002年畢業於中國協和醫科大學藥物研究所，師從郭宗儒教授，開展抗炎藥物的研究，獲得博士學位。2002年-2006年在美國西北大學醫學院從事博士後研究,開展神經退行性疾病的藥物研究。2006年-2016年在中國科學院廣州生物醫藥與健康研究院歷任副研究員、研究員、新藥開發室主任。

在歷時20多年的新藥研究中,胡教授團隊已確立多個全新結構的候選藥物。其中，基於神經膠質細胞功能障礙的抗阿爾茨海默氏症新藥AD16（GIBH130、哌達甲酮），已獲得國家食品藥品監督管理局（CFDA）頒發的1.1類藥物臨床試驗批件（ 批件號：2016L02442，2016L02443，2016L02444），化合物專利涵蓋了全球多個國家。相關的研究以通訊作者的論文發表在Angewandte Chemie International Edition，Journal of Medicinal Chemistry、Organic Letters、European Journal of Medicinal Chemistry等學術刊物，並在Advanced Synthesis & Catalysis, ChemCatChem和科學通報上發表了封面文章。

基本介紹

  • 中文名：胡文輝
  • 性 別： 男
  • 職 稱：研究員
  • 學 歷： 博士
個人信息,

個人信息

主要科研項目及成果：立足於尚無有效藥物的重大疾病，開展化學生物學和創新藥物的研究，解決關鍵的科學問題或研發具有開發前景的新藥，建立國內具有特色和優勢的新藥研發團隊。胡教授已申請了30多項國際和國家發明專利，主持國家科技部、廣東省科技廳的新藥重大專項，企業橫向經費等各類新藥基金2000多萬元，發表了30多篇國際學術論文，兼任藥學學報的青年編委。
代表性學術論文：
  1. Hui Xie, Shaogao Zeng, Yuwen He, Guicheng Zhang, Pengjiu Yu, Guifa Zhong, Hongjiang Xu, Ling Yang, Shanchun Wang, Xin Zhao*, Wenhui Hu*. Rapid generation of a novel DPP-4 inhibitor with long-acting properties: SAR study and PK/PD evaluation. European Journal of Medicinal Chemistry, 2017, 141, 519-529. (IF=4.5)
  2. Yunlong Zhao, Qingxin Zhao, LS Wang, Wen Hui Hu*, Jun Ling Zhao*. Organocatalytic Friedel-Crafts Alkylation /Lactonization Reaction of Naphthols with 3-Trifluoroethylidene Oxindoles: The Asymmetric Synthesis of Dihydrocoumarins. AngewandteChemie International Edition. 2017, 56, 338 –342. (IF =12.0)
  3. Wei Zhou, Guifa Zhong, Sihai Fu, Hui Xie, Tianyan Chi, Luyi Li, Xiurong Rao，Shaogao Zeng, Dengfeng Xu, Hao Wang, Guoqing Sheng, Xing Ji, Xiaorong Liu, Xuefei Ji, Donghai Wu, Libo Zou, Micky Tortorella, Kejian Zhang, and Wenhui Hu*. Microglia-based phenotypic screening identifies a novel inhibitor of neuroinflammation effective in Alzheimer's Disease Models. ACS Chemical Neuroscience. 2016, Nov 16;7 (11):1499-1507. (IF =3.9)
  4. Jianghong Dong, Shengwei Chen, Runfeng Li, Wei Cui, Haiming Jiang, Yixia Ling, Zifeng Yang, Wenhui Hu*. Imidazole-based pinanamine derivatives: Discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus. European Journal of Medicinal Chemistry. 2016, 108,605-615. (IF=4.5)
  5. Shengwei Chen, Qinxin Lou, Yuyang Ding, Shasha Zhang, Wenhui Hu* and Junling Zhao* Organocatalytic enantioselective Michael reaction of malononitrile to b,b-disubstituted nitroalkenes. Advanced Synthesis & Catalysis. 2015, 357, 2437-2441. (Front Cover and Very Important Publication). (IF =5.6)
  6. Shengwei Chen, Guicheng Zhang, Qxinxin Lou, Wei Cui, Shasha Zhang, Wenhui Hu* and Junling Zhao*. Organocatalytic enantioselective aza-Michael reaction of benzotriazole to β,β-disubstituted nitroalkenes. ChemCatChem. 2015, 7, 1935-1938. (Inside Back Cover). (IF =4.8)
  7. Yuyang Ding, Liufeng Mao, Dengfeng Xu, Hui Xie, Ling Yang, Hongjiang Xu, Wenjun Geng, Yong Gao, Chunguang Xia, Xiquan Zhang, Qingyi Meng, Donghai Wu, Junling Zhao * and Wenhui Hu*. C-aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents. Bioorganic Medinal Chemistry letter. 2015, 25, 2744-2748. (IF =2.8)
  8. Bo Bi, Qin-Xin Lou, Yu-Yang Ding, Sheng-Wei Chen, Sha-Sha Zhang, Wen-Hui Hu* and Jun-Ling Zhao* Chiral phosphoric acid-catalyzed highly enantioselective Friedel-Crafts alkylation reaction of C3-substituted indoles to unsaturated ketimino esters.Organic Letters, 2015, 17, 540−543.(IF =6.6)
  9. Wei Cui, Shengwei Chen, JiaQiang Wu, Xin Zhao*,Wenhui Hu*, and Honggen Wang*, Palladium-Catalyzed Remote C(sp3)−H Arylation of 3‑Pinanamine. Organic Letters.2014, 16, 4288−4291.(IF =6.6)
  10. 周渭, 胡文輝. 神經炎症抑制劑用於阿爾茨海默症的藥物研發. 科學通報. 2014. 59(3): 232 - 237. （封面文章）
  11. Wei Zhou, Wenhui Hu*. Anti-neuroinflammatory agents for the treament of Alzheimer’s disease. Future Medicinal Chemistry. 2013.5 (13): 1-13. (IF =3.6)
  12. Hui Xie, Lili Zeng, Shaogao Zeng, Xin Lu, Xin Zhao, Guicheng Zhang, Zhengchao Tu, Hongjiang Xu, Ling Yang, Xiquan Zhang, Shanchun Wang*, Wenhui Hu*. Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization. European Journal of Medicinal Chemistry. 2013, 68, 312-320. (IF=4.5)
  13. Shaogao Zeng, Hui Xie, L-li Zeng, Xin Lu, Xin Zhao, Gui-cheng Zhang, Zhengchao Tu, Hongjiang Xu, Ling Yang, Xiquan Zhang, Wenhui Hu*. Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization.Bioorganic & Medicinal Chemistry. 2013. 21(7):1749-55. (IF=2.9)
  14. Xin Zhao, Yanling Jie, Matthew R. Rosenberg, Junting Wan, Shaogao Zeng, Wei Cui, Yiping Xiao, Zhiyuan Li, Zhengchao Tu, Marco G. Casarotto, Wenhui Hu*. Design and Synthesis of Pinanamine Derivatives as Anti-Influenza A M2 Ion Channel Inhibitors. Antiviral Research. 2012, 96(2):91-99. (IF=4.3)
  15. Wei Zhou, Guifa Zhong, Xiurong Rao, Hui Xie, Shaogao Zeng, Tianyan Chi, Libo Zou, Donghai Wu, Wenhui Hu*. Identification of aminopyridazine-derived anti-neuroinflammatory agents effective in an alzheimer’s mouse model. ACS Medicinal Chemistry Letters. 2012, 3 (11): 903–907. (IF=3.7)
  16. Hui Xie, Lili Zeng, Shaogao Zeng, Xin Lu, Guicheng Zhang, Xin Zhao, Na Cheng, Zhengchao Tu, Zhiyuan Li, Hongjiang Xu, Ling Yang, Xiquan Zhang, Min Huang, and Wenhui Hu*. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. European Journal of Medicinal Chemistry. 2012, 52:205-12. (IF=4.5)
  17. Hong Li, Junling Zhao, Lili Zeng, Wenhui Hu*. Organocatalytic asymmetric domino aza-Michael-Mannich reaction: synthesis of tetrahydroimidazopyrimidine derivatives. Journal of Organic Chemistry. 2011, 76(19): 8064-9. (IF=4.8)
  18. Xin Zhao, Chufang Li, Shaogao Zeng, Wenhui Hu*. Discovery of highly potent agents against influenza A virus. European Journal of Medicinal Chemistry. 2011, 46 (1):52-57. (IF=4.5)
  19. Jifeng Deng, Li Peng, Guicheng Zhang, Xiaobing Lan, Chufang Li, Fuxin Chen, Yayao Zhou, Zuoxian Lin, Ling Chen, Renke Dai, Hongjiang Xu, Ling Yang, Xiquan Zhang, Wenhui Hu*. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes. European Journal of Medicinal Chemistry.2011, 46 (1): 71-76. (IF=4.5)
  20. Wenhui Hu*, Shaogao Zeng, Chufang Li，Yanling Jie, Zhiyuan Li and Ling Chen. Identification of Hits as Matrix-2 Inhibitors through the Focused Screening of a Small Primary Amine Library.Journal of Medicinal Chemistry. 2010, 53(9): 3831-3834. (IF=6.3)

相關詞條

熱門詞條

聯絡我們